How is stem cell treatment for cerebral palsy done?
At Stem Cell Mexico, stem cell treatment for cerebral palsy (CP) is a structured, minimally invasive process designed around the patient's age, weight, health and goals.

It begins with a review of medical and therapy records, continues with a consultation with the doctor, a written plan, careful preparation and an in-person evaluation, and centers on the application of allogeneic mesenchymal stem cells (MSCs) from Wharton's jelly of the umbilical cord, usually by intravenous (IV) infusion with doses adjusted to body weight. Treatment is followed by observation, discharge with written instructions and structured follow-up coordinated with the patient's therapists. No autologous cells, cord blood or other cell sources are used. The number of applications is not fixed in advance; it is defined individually and only when there is a medical reason.
This guide walks families through each step, with practical advice for traveling with a child or adult with CP.
Why preparation matters so much in CP
People with CP often have associated conditions that affect how a medical procedure should be planned: epilepsy, swallowing difficulties, reflux, respiratory problems, nutritional challenges, sensory sensitivities, communication differences and mobility needs. A careful plan reduces risk and stress for the patient and the family. This is why the process begins weeks before the visit.
A typical itinerary
A common itinerary looks like this:
- Day 1: pickup in the San Diego area, border crossing with a driver, laboratory tests and in-person consultation with the doctor, then rest at a nearby hotel or at the clinic.
- Day 2: IV infusion of Wharton's jelly MSCs, followed by observation, usually overnight with a parent or caregiver present.
- Day 3: check-up with the doctor, discharge instructions and return to San Diego.
Families can request wheelchair-accessible transport, quiet rooms and extra time for feeding or rest. The exact itinerary is confirmed in your written plan.
Step 1: Records review
The family sends:
- Neurology reports and diagnosis of CP type.
- Brain imaging reports (MRI or CT), if available.
- GMFCS level and recent therapy assessments, ideally including GMFM scores.
- Seizure history and current anti-seizure medications.
- Feeding and respiratory information: swallowing studies, feeding tubes, history of pneumonia.
- Complete medication list, including baclofen, botulinum toxin injections and supplements.
- Weight and height, since doses are calculated per kilogram.
- Short videos of current abilities, which help the doctor understand function and later serve as a baseline.
Step 2: Consultation with the doctor
A complimentary phone or video consultation allows the doctor to understand the patient's history, discuss goals with the family and explain what regenerative treatment can and cannot do for CP. Goals are made specific, for example improving sitting balance, walking endurance, hand use, tone or engagement in therapy, so progress can be measured.
Step 3: Written plan and preparation
If treatment is considered appropriate, the family receives a written plan with the cell dose, route, itinerary, inclusions and costs. Preparation usually includes:
- Continuing anti-seizure medications exactly as prescribed; they are never skipped.
- Pausing anti-inflammatory painkillers, supplements such as omega 3, turmeric and ginger, and other products as the doctor indicates.
- Planning fasting instructions adapted to age and feeding method.
- Bringing mobility equipment, positioning supports, feeding supplies and comfort items.
- Preparing the child with simple explanations, pictures or social stories about the visit.
Step 4: Arrival and evaluation
On arrival, the patient has blood tests appropriate to age and health and an in-person examination with the doctor. Vital signs, weight, neurological status and current abilities are documented. If the patient has a fever, an infection, a recent seizure cluster or any other sign that treatment would not be safe that day, it is postponed.
Step 5: The cell application
The cells
Allogeneic MSCs from Wharton's jelly of donated umbilical cords, obtained after healthy, full-term births with informed consent and donor screening. They are produced in a COFEPRIS-licensed laboratory under Good Manufacturing Practice standards, with quality and safety testing before release.
The IV infusion
- A topical anesthetic cream may be applied to reduce discomfort before the IV is placed.
- A small catheter is placed in a vein, with a parent or caregiver nearby.
- Baseline vital signs are recorded.
- The cells are infused slowly, usually over 30 to 60 minutes, with the volume adjusted to body size.
- Heart rate, oxygen, blood pressure and temperature are monitored during and after the infusion.
The IV route avoids surgery and generally does not require sedation. It is the route used in the randomized trial of umbilical cord MSCs in children with CP published in Stem Cell Research & Therapy, in which children received IV infusions alongside rehabilitation.
Other routes
Some studies have used intrathecal delivery (into the spinal fluid through a lumbar puncture). This route may require sedation in children and carries risks such as headache, back pain and, rarely, infection. It is considered only when the medical team judges it appropriate for the specific case and protocol, and its risks are reviewed with the family beforehand.
Step 6: Observation
After the infusion, the patient remains under nursing and medical supervision, usually overnight, with a parent or caregiver present. The team watches for:
- Fever, the most common reaction, usually mild and temporary. In children with epilepsy, temperature is monitored closely because fever can lower the seizure threshold.
- Irritability, headache or fatigue.
- Breathing and feeding, especially in patients with swallowing difficulties.
Paracetamol (acetaminophen) and cooling measures are used if fever appears.
Step 7: Discharge and recovery at home
Before discharge, the doctor reviews vital signs and how the patient is feeling, and gives written instructions:
- Rest on the day of treatment and the following day.
- Mild fever, fussiness or tiredness for a day or two may occur.
- Continue all medications, especially anti-seizure medications.
- Resume therapy as advised, usually within a few days.
- Seek care promptly for high or persistent fever, breathing difficulty, seizures that differ from the usual pattern or any concerning symptom.
No treatment is free of risk, and families are encouraged to contact the clinic with any question after returning home.
Step 8: Follow-up and measurement
- Follow-up calls at regular intervals to review progress and any concerns.
- Repeat assessments at about 3, 6 and 12 months, ideally by the same therapists and with the same scales used at baseline.
- Videos of the same activities recorded at baseline, for comparison.
- Coordination with the patient's neurologist, pediatrician and therapy team.
In the controlled trial of umbilical cord MSCs, motor differences between groups became evident about 6 months after treatment, so families should allow time before judging results.
The role of rehabilitation
The U.S. Centers for Disease Control and Prevention (CDC) emphasizes early and continued intervention for CP. Physical, occupational and speech therapy remain the foundation of care before and after any cell treatment. Many families plan a period of more intensive therapy in the months after treatment to make the most of any potential benefit.
Sharing the treatment date and the follow-up schedule with your therapists ahead of time allows them to plan baseline and repeat assessments and to adjust goals in the months that follow.
Tips for traveling with a person with CP
- Plan rest stops and allow extra time at the border crossing; the driver can help with mobility equipment.
- Bring documentation: passports for everyone, a medication list, the neurology report and the seizure action plan, if one exists.
- Pack familiar items: favorite toys, blankets, headphones or tablets can reduce stress in a new environment.
- Bring enough medication for the full trip plus extra days in case of delays.
- Feeding supplies: special formulas, thickeners, feeding tube equipment and utensils the patient is used to.
- Two caregivers, when possible, make transfers, feeding and overnight care easier.
Telling the coordination team in advance about sensory sensitivities, communication methods or behavioral needs allows staff to adapt the environment and approach.
Who may be a candidate
- Children and adults with a confirmed diagnosis of CP.
- Seizures controlled with medication, if present.
- Stable respiratory and nutritional status.
- No active infection and no cancer.
- Ongoing participation in rehabilitation and realistic expectations.
Questions to ask during your evaluation
- Which dose, route and number of applications are proposed, and why?
- Will sedation be needed?
- How will seizures, feeding and breathing be managed during the stay?
- Which assessments should we bring and repeat afterward?
- How should we coordinate with our therapists?
Bottom line
Stem cell treatment for cerebral palsy at Stem Cell Mexico follows a careful, step-by-step process: records review, consultation, individualized preparation, evaluation, IV application of Wharton's jelly MSCs with monitoring, observation with a caregiver present and structured follow-up alongside rehabilitation. Results vary between patients. A medical evaluation can help determine whether this type of regenerative treatment is appropriate for your child's or your own condition, goals and medical history.
References
- U.S. Centers for Disease Control and Prevention (CDC): Treatment and intervention for cerebral palsy (opens in a new tab)
- Gu J et al. Therapeutic evidence of umbilical cord-derived mesenchymal stem cell transplantation for cerebral palsy: a randomized, controlled trial. Stem Cell Research & Therapy, 2020 (opens in a new tab)
- Caplan H, Olson SD, Cox CS Jr et al. Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application. Frontiers in Immunology, 2019 (opens in a new tab)
- Hum C et al. Safety of intravascular administration of umbilical-cord-derived mesenchymal stromal cells: an updated systematic review and meta-analysis. Stem Cells Translational Medicine, 2026 (opens in a new tab)
